Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) – Analysts at Leerink Swann increased their FY2016 EPS estimates for Zeltiq Aesthetics in a research report issued to clients and investors on Thursday. Leerink Swann analyst R. Newitter now forecasts that the brokerage will post earnings per share of ($0.08) for the year, up from their prior estimate of ($0.21). Leerink Swann has a “Outperform” rating and a $48.00 price objective on the stock. Leerink Swann also issued estimates for Zeltiq Aesthetics’ Q1 2017 earnings at ($0.14) EPS, Q2 2017 earnings at $0.03 EPS, Q3 2017 earnings at $0.18 EPS and Q4 2017 earnings at $0.20 EPS.

Zeltiq Aesthetics (NASDAQ:ZLTQ) last announced its earnings results on Wednesday, November 9th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of $0.08 by $0.04. The business earned $95.20 million during the quarter, compared to the consensus estimate of $90.84 million. Zeltiq Aesthetics had a net margin of 9.48% and a negative return on equity of 6.45%. Zeltiq Aesthetics’s revenue was up 55.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.05 EPS.

Earnings History and Estimates for Zeltiq Aesthetics (NASDAQ:ZLTQ)

ZLTQ has been the topic of several other research reports. Zacks Investment Research upgraded shares of Zeltiq Aesthetics from a “hold” rating to a “buy” rating and set a $41.00 price objective on the stock in a report on Wednesday, October 26th. Brean Capital restated a “buy” rating on shares of Zeltiq Aesthetics in a report on Monday, October 24th. Stifel Nicolaus upped their price objective on shares of Zeltiq Aesthetics from $38.00 to $52.00 and gave the stock a “buy” rating in a report on Wednesday, September 21st. JPMorgan Chase & Co. restated a “hold” rating and set a $35.00 price objective (up previously from $27.00) on shares of Zeltiq Aesthetics in a report on Tuesday, August 9th. Finally, Maxim Group upped their price objective on shares of Zeltiq Aesthetics from $40.00 to $48.00 and gave the stock a “buy” rating in a report on Tuesday, August 9th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Zeltiq Aesthetics has an average rating of “Buy” and an average target price of $42.78.

Shares of Zeltiq Aesthetics (NASDAQ:ZLTQ) opened at 39.41 on Monday. The company has a market cap of $1.57 billion, a P/E ratio of 50.85 and a beta of 0.89. Zeltiq Aesthetics has a one year low of $18.41 and a one year high of $41.48. The company’s 50 day moving average is $37.67 and its 200 day moving average is $33.39.

In related news, VP Bradley Hauser sold 3,000 shares of the firm’s stock in a transaction dated Monday, September 12th. The shares were sold at an average price of $37.33, for a total transaction of $111,990.00. Following the completion of the sale, the vice president now owns 46,240 shares in the company, valued at $1,726,139.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Keith J. Sullivan sold 8,000 shares of the firm’s stock in a transaction dated Tuesday, September 6th. The stock was sold at an average price of $38.36, for a total transaction of $306,880.00. Following the sale, the insider now owns 83,159 shares of the company’s stock, valued at approximately $3,189,979.24. The disclosure for this sale can be found here. 15.60% of the stock is currently owned by insiders.

A number of hedge funds have recently bought and sold shares of ZLTQ. EULAV Asset Management bought a new stake in Zeltiq Aesthetics during the third quarter worth about $1,961,000. Profund Advisors LLC bought a new stake in Zeltiq Aesthetics during the third quarter worth about $229,000. Principal Financial Group Inc. increased its stake in Zeltiq Aesthetics by 13.3% in the third quarter. Principal Financial Group Inc. now owns 258,021 shares of the company’s stock worth $10,120,000 after buying an additional 30,357 shares during the period. Zevenbergen Capital Investments LLC bought a new stake in Zeltiq Aesthetics during the third quarter worth about $11,133,000. Finally, Northern Trust Corp increased its stake in Zeltiq Aesthetics by 4.9% in the third quarter. Northern Trust Corp now owns 636,401 shares of the company’s stock worth $24,960,000 after buying an additional 29,969 shares during the period.

Zeltiq Aesthetics Company Profile

ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is designed to reduce stubborn fat bulges. It sell the CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists, and obstetrics and gynecology physicians.

5 Day Chart for NASDAQ:ZLTQ

Receive News & Stock Ratings for Zeltiq Aesthetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zeltiq Aesthetics Inc. and related stocks with our FREE daily email newsletter.